File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma

TitleSurvival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma
Authors
Keywordsradiofrequency ablation
recurrent HCC
recurrence
high-intensity focused ultrasound
hepatocellular carcinoma
Issue Date2013
Citation
Annals of Surgery, 2013, v. 257, n. 4, p. 686-692 How to Cite?
AbstractOBJECTIVE: To evaluate our preliminary experience of high-intensity focused ultrasound (HIFU) for the treatment of recurrent hepatocellular carcinoma (HCC). BACKGROUND: HIFU is a new thermal ablative therapy for HCC. Whether it incurs survival benefit similar to that of radiofrequency ablation (RFA) remains uncertain. METHODS: Clinicopathological data of 27 patients who received HIFU ablation and 76 patients who received RFA for recurrent HCC from October 2006 to October 2009 were reviewed. Survival outcomes between the 2 groups were compared using the log-rank test. A value of P < 0.05 was considered significant. RESULTS: The median follow-up was 27.9 months. There was no difference in tumor size (HIFU, 1.7 cm; RFA, 1.8 cm; P = 0.28) between the 2 groups. Procedure-related morbidity rate was 7.4% in the HIFU group and 6.5% in the RFA group (P = 1.00). Skin burn and pleural effusion were the 2 morbidities associated with HIFU. There was no hospital mortality in the HIFU group, whereas 2 deaths occurred in the RFA group. The 1-, 2-, and 3-year disease-free survival rates were 37.0%, 25.9%, and 18.5%, respectively, for the HIFU group, and 48.6%, 32.1%, and 26.5%, respectively for the RFA group (P = 0.61). The 1-, 2-, and 3-year overall survival rates were 96.3%, 81.5%, and 69.8%, respectively, for the HIFU group, and 92.1%, 76.1%, and 64.2%, respectively, for the RFA group (P = 0.19). CONCLUSIONS: Our preliminary experience in using HIFU for recurrent HCC is promising. Further studies are needed to explore its treatment value for primary HCC. Copyright © 2013 by Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/221336
ISSN
2015 Impact Factor: 8.569
2015 SCImago Journal Rankings: 4.503
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, ACY-
dc.contributor.authorCheung, TT-
dc.contributor.authorFan, ST-
dc.contributor.authorChok, KSH-
dc.contributor.authorChan, SC-
dc.contributor.authorPoon, RTP-
dc.contributor.authorLo, CM-
dc.date.accessioned2015-11-18T06:09:02Z-
dc.date.available2015-11-18T06:09:02Z-
dc.date.issued2013-
dc.identifier.citationAnnals of Surgery, 2013, v. 257, n. 4, p. 686-692-
dc.identifier.issn0003-4932-
dc.identifier.urihttp://hdl.handle.net/10722/221336-
dc.description.abstractOBJECTIVE: To evaluate our preliminary experience of high-intensity focused ultrasound (HIFU) for the treatment of recurrent hepatocellular carcinoma (HCC). BACKGROUND: HIFU is a new thermal ablative therapy for HCC. Whether it incurs survival benefit similar to that of radiofrequency ablation (RFA) remains uncertain. METHODS: Clinicopathological data of 27 patients who received HIFU ablation and 76 patients who received RFA for recurrent HCC from October 2006 to October 2009 were reviewed. Survival outcomes between the 2 groups were compared using the log-rank test. A value of P < 0.05 was considered significant. RESULTS: The median follow-up was 27.9 months. There was no difference in tumor size (HIFU, 1.7 cm; RFA, 1.8 cm; P = 0.28) between the 2 groups. Procedure-related morbidity rate was 7.4% in the HIFU group and 6.5% in the RFA group (P = 1.00). Skin burn and pleural effusion were the 2 morbidities associated with HIFU. There was no hospital mortality in the HIFU group, whereas 2 deaths occurred in the RFA group. The 1-, 2-, and 3-year disease-free survival rates were 37.0%, 25.9%, and 18.5%, respectively, for the HIFU group, and 48.6%, 32.1%, and 26.5%, respectively for the RFA group (P = 0.61). The 1-, 2-, and 3-year overall survival rates were 96.3%, 81.5%, and 69.8%, respectively, for the HIFU group, and 92.1%, 76.1%, and 64.2%, respectively, for the RFA group (P = 0.19). CONCLUSIONS: Our preliminary experience in using HIFU for recurrent HCC is promising. Further studies are needed to explore its treatment value for primary HCC. Copyright © 2013 by Lippincott Williams & Wilkins.-
dc.languageeng-
dc.relation.ispartofAnnals of Surgery-
dc.subjectradiofrequency ablation-
dc.subjectrecurrent HCC-
dc.subjectrecurrence-
dc.subjecthigh-intensity focused ultrasound-
dc.subjecthepatocellular carcinoma-
dc.titleSurvival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1097/SLA.0b013e3182822c02-
dc.identifier.pmid23426335-
dc.identifier.scopuseid_2-s2.0-84875214571-
dc.identifier.hkuros213636-
dc.identifier.volume257-
dc.identifier.issue4-
dc.identifier.spage686-
dc.identifier.epage692-
dc.identifier.eissn1528-1140-
dc.identifier.isiWOS:000315990100024-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats